GENB
GENERATE BIOMEDICINES INCData as of 2026 Q2 (06-30) · 13F snapshot
Summary
GENERATE BIOMEDICINES INC (GENB) is held as common stock by 4 tracked hedge-fund managers, with a combined reported value of ~$46.73M; the largest are Baker Bros. Advisors, Cathie Wood, Renaissance Technologies. This quarter: 1 new, 1 added, 1 trimmed, 1 closed. Data as of 2026 Q2, from public SEC 13F filings, delayed up to ~45 days.
Attention · MediumThis quarter · Mixed
Common-stock holders4
Congress trades0
Price$14.91vs quarter-end-11.62%
Sectors0
This quarter's moves
Top holderBaker Bros. AdvisorsNew1
Added1
Trimmed / sold2
Common-stock positions
PUT and CALL disclosures are excluded from these holder counts and values.
Value $24.02M0.1% of portfolio1,423,6022026 Q2
| Investor | Value | % of portfolio | Action |
|---|---|---|---|
| Baker Bros. Advisors | $24.02M | 0.1% | Hold |
ARK ETF holdings
Cathie Wood · dailyARK total shares held · drag to inspect
2026-09-29holds 1,545,379
- ARKGweight in fund1.06%$23.04M
ARK publishes full ETF holdings daily (SEC Rule 6c-11). Line shows ARK's total shares held over time (not price); markers are buy/sell days. Derived from public CSVs — research only, not investment advice.
Public SEC 13F filings may appear up to 45 days after quarter-end; STOCK Act / OGE trade filings are generally due within 45 days but may be late. Partial data only — research, not investment advice.